CLAIMS

1. A compound according to Formula (XIX), or a pharmaceutically acceptable salt thereof:



(XIX)

wherein:

A^1 is CH, A^2 is O, and A^3 is N; or A^1 is CH, A^2 is N, and A^3 is O; or A^1 is CH, A^2 is N, and A^3 is NR^{15};

Z^1, Z^2, Z^3, and Z^4 are each independently N, CH, or CR^6, wherein 0, 1, or 2 of Z^1, Z^2, Z^3, and Z^4 are N and 0, 1, or 2 of Z^1, Z^2, Z^3, and Z^4 are CR^6;

R^2 is hydrogen, $(C_1$-$C_4)$alkyl, or $(C_1$-$C_4)$alkoxy;

R^3 is hydrogen, hydroxyl, $(C_1$-$C_4)$alkoxy, or $(C_3$-$C_6)$cycloalkoxy;

R^5 is hydrogen, hydroxyl, $(C_1$-$C_4)$alkoxy, or $(C_3$-$C_6)$cycloalkoxy;

each R^6 is independently selected from the group consisting of fluorine, chlorine, methyl, ethyl, difluoromethyl, cyclopropyl, methoxy, isopropoxy, and dimethylamino-;

R^{14} is $(C_1$-$C_4)$alkyl or halo$(C_1$-$C_4)$alkyl; and

R^{15} is hydrogen, methyl, ethyl, or phenyl.

2. The compound or pharmaceutically acceptable salt according to claim 1, wherein A^1 is CH, A^2 is O, and A^3 is N.

3. The compound or pharmaceutically acceptable salt according to claim 1, wherein two of Z^1, Z^2, Z^3, and Z^4 are N and the other two are each independently CH or CR^6.

4. The compound or pharmaceutically acceptable salt according to claim 1, wherein R^2 is hydrogen.

5. The compound or pharmaceutically acceptable salt according to claim 1, wherein R^3 is hydrogen or $(C_1$-$C_4)$alkoxy.

6. The compound or pharmaceutically acceptable salt according to claim 1, wherein R^5 is hydrogen or $(C_1$-$C_4)$alkoxy.

7. The compound or pharmaceutically acceptable salt according to claim 1, wherein:

A^1 is CH, A^2 is O, and A^3 is N;

two of Z^1, Z^2, Z^3, and Z^4 are N and the other two are each independently CH or CR^6;

R^2 is hydrogen;

R^3 is hydrogen or $(C_1$-$C_4)$alkoxy;

R^5 is hydrogen or $(C_1$-$C_4)$alkoxy;

each R^6 is independently selected from the group consisting of fluorine, chlorine, methyl, ethyl, difluoromethyl, cyclopropyl, methoxy, isopropoxy, and dimethylamino-; and

R^{14} is $(C_1$-$C_4)$alkyl or halo$(C_1$-$C_4)$alkyl.

8. The compound according to claim 1 which is:



;

or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1 which is:



10. The compound according to claim 9 in crystalline form.

11. The compound according to claim 10, wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three diffraction angles, when measured using Cu K_α radiation, selected from a group consisting of about 2.2, 4.9, 5.5, 5.7, 11.8, 11.9, 12.8, 12.9, 13.1, 14.3, 16.1, 16.6, 17.1, 17.2, 21.2, 21.3, 21.9, 22.0, 22.7, 22.8, 23.1, 25.3, and 25.4 degrees 2θ.

12. The compound according to claim 10, wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern comprising diffraction angles, when measured using Cu K_α radiation, of about 5.7, 11.9, 12.9, 14.3, 16.1, and 23.1 degrees 2θ.

13. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 1 and a pharmaceutically acceptable excipient.

14. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 8 and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition comprising the compound according to claim 12 and a pharmaceutically acceptable excipient.

17. The compound or pharmaceutically acceptable salt according to claim 1 for use in the treatment of irritable bowel syndrome, excluding the following compound or its pharmaceutically acceptable salt:



;

the following compound



;

and the following compound



in crystalline form, wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern comprising diffraction angles, when measured using Cu K_α radiation, of about 5.7, 11.9, 12.9, 14.3, 16.1, and 23.1 degrees 2_Θ.

18. The compound or pharmaceutically acceptable salt according to claim 8 for use in the treatment of irritable bowel syndrome.

19. The compound according to claim 9 for use in the treatment of irritable bowel syndrome.

20. The compound according to claim 12 for use in the treatment of irritable bowel syndrome.

21. Use of a compound or pharmaceutically acceptable salt according to claim 1 in the manufacture of a medicament for the treatment of irritable bowel syndrome, excluding the following compound or its pharmaceutically acceptable salt:



;

the following compound



;

and the following compound



in crystalline form, wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern comprising diffraction angles, when measured using Cu K_α radiation, of about 5.7, 11.9, 12.9, 14.3, 16.1, and 23.1 degrees 2_Θ.

22. Use of a compound or pharmaceutically acceptable salt according to claim 8 in the manufacture of a medicament for the treatment of irritable bowel syndrome.

23. Use of a compound according to claim 9 in the manufacture of a medicament for the treatment of irritable bowel syndrome.

24**.** Use of a compound according to claim 12 in the manufacture of a medicament for the treatment of irritable bowel syndrome.